These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 19033369)

  • 41. Pharmacokinetic and Pharmacodynamic Profiles of Ethinylestradiol/Norgestimate Combination or Norethindrone upon Coadministration with Elagolix 150 mg Once Daily in Healthy Premenopausal Women.
    Feldman RA; Chiu YL; Klein CE; Ng J
    Clin Pharmacokinet; 2021 Aug; 60(8):1003-1013. PubMed ID: 33748934
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Drug-Drug Interaction Studies of Elagolix with Oral and Transdermal Low-Dose Hormonal Add-Back Therapy.
    Nader A; Mostafa NM; Ali F; Shebley M
    Clin Pharmacokinet; 2021 Jan; 60(1):133-143. PubMed ID: 32696440
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacodynamic effects and plasma pharmacokinetics of single doses of cetrorelix acetate in healthy premenopausal women.
    Erb K; Klipping C; Duijkers I; Pechstein B; Schueler A; Hermann R
    Fertil Steril; 2001 Feb; 75(2):316-23. PubMed ID: 11172833
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity.
    Rossmanith WG; Steffens D; Schramm G
    Contraception; 1997 Jul; 56(1):23-30. PubMed ID: 9306028
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Elagolix for endometriosis: all that glitters is not gold.
    Vercellini P; Viganò P; Barbara G; Buggio L; Somigliana E;
    Hum Reprod; 2019 Feb; 34(2):193-199. PubMed ID: 30551159
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hypothalamic-pituitary-gonadal axis in two men with aromatase deficiency: evidence that circulating estrogens are required at the hypothalamic level for the integrity of gonadotropin negative feedback.
    Rochira V; Zirilli L; Genazzani AD; Balestrieri A; Aranda C; Fabre B; Antunez P; Diazzi C; Carani C; Maffei L
    Eur J Endocrinol; 2006 Oct; 155(4):513-22. PubMed ID: 16990650
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas.
    Dababou S; Garzon S; Laganà AS; Ferrero S; Evangelisti G; Noventa M; D'Alterio MN; Palomba S; Uccella S; Franchi M; Barra F
    Expert Opin Investig Drugs; 2021 Sep; 30(9):903-911. PubMed ID: 34278887
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Assessment of pituitary gonadotropin release to gonadotropin releasing hormone/thyroid-stimulating hormone stimulation in women with systemic sclerosis.
    La Montagna G; Baruffo A; Pasquali D; Bellastella A; Tirri G; Sinisi AA
    Rheumatology (Oxford); 2001 Mar; 40(3):310-4. PubMed ID: 11285379
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
    Kazem R; Messinis LE; Fowler P; Groome NP; Knight PG; Templeton AA
    Hum Reprod; 1996 Dec; 11(12):2585-90. PubMed ID: 9021355
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of an antiprogesterone (RU486) on the hypothalamic-hypophyseal-ovarian-endometrial axis during the luteal phase of the menstrual cycle.
    Garzo VG; Liu J; Ulmann A; Baulieu E; Yen SS
    J Clin Endocrinol Metab; 1988 Mar; 66(3):508-17. PubMed ID: 2832438
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacokinetic and pharmacodynamic modeling of cetrorelix, an LH-RH antagonist, after subcutaneous administration in healthy premenopausal women.
    Nagaraja NV; Pechstein B; Erb K; Klipping C; Hermann R; Niebch G; Derendorf H
    Clin Pharmacol Ther; 2000 Dec; 68(6):617-25. PubMed ID: 11180022
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Single-dose administration of the gonadotropin-releasing hormone antagonist, Nal-Lys (antide) to healthy men.
    Bagatell CJ; Conn PM; Bremner WJ
    Fertil Steril; 1993 Oct; 60(4):680-5. PubMed ID: 8405525
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oral Gonadotropin-Releasing Hormone Antagonists in the Treatment of Uterine Myomas: A Systematic Review and Network Meta-analysis of Efficacy Parameters and Adverse Effects.
    Telek SB; Gurbuz Z; Kalafat E; Ata B
    J Minim Invasive Gynecol; 2022 May; 29(5):613-625. PubMed ID: 34942350
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells.
    Minaretzis D; Alper MM; Oskowitz SP; Lobel SM; Mortola JF; Pavlou SN
    Am J Obstet Gynecol; 1995 May; 172(5):1518-25. PubMed ID: 7755066
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ovulation inhibition by daily i.m. administration of a highly active LH-RH analog (d-ser(TBU)6-LH-RH-(1-9)-nonapeptide-ethylamide).
    Baumann R; Kuhl H; Taubert HD; Sandow J
    Contraception; 1980 Feb; 21(2):191-7. PubMed ID: 6768492
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Elagolix treatment for endometriosis-associated pain: results from a phase 2, randomized, double-blind, placebo-controlled study.
    Diamond MP; Carr B; Dmowski WP; Koltun W; O'Brien C; Jiang P; Burke J; Jimenez R; Garner E; Chwalisz K
    Reprod Sci; 2014 Mar; 21(3):363-71. PubMed ID: 23885105
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Suppression of corpus luteum function by the gonadotropin-releasing hormone antagonist Nal-Glu: effect of the dose and timing of human chorionic gonadotropin administration.
    Dubourdieu S; Charbonnel B; Massai MR; Marraoui J; Spitz I; Bouchard P
    Fertil Steril; 1991 Sep; 56(3):440-5. PubMed ID: 1894021
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical Utility Of Elagolix As An Oral Treatment For Women With Uterine Fibroids: A Short Report On The Emerging Efficacy Data.
    Neri M; Melis GB; Giancane E; Vallerino V; Pilloni M; Piras B; Loddo A; Paoletti AM; Mais V
    Int J Womens Health; 2019; 11():535-546. PubMed ID: 31695514
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Elagolix treatment in women with heavy menstrual bleeding associated with uterine fibroid: a systematic review and meta-analysis.
    Muhammad J; Yusof Y; Ahmad I; Norhayati MN
    BMC Womens Health; 2022 Jan; 22(1):14. PubMed ID: 35033041
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Short-term endocrine response to gonadotropin-releasing hormone agonist initiated in the early follicular, midluteal, or late luteal phase in normally cycling women.
    Gelety TJ; Pearlstone AC; Surrey ES
    Fertil Steril; 1995 Dec; 64(6):1074-80. PubMed ID: 7589655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.